```
line 16, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 8)--;
hine 20, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 9)--;
hine 30-31, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 10)--;
hines 33-34, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 11)--;
hine 17, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 12)--;
line 18, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 13)--;
hine 24, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 14)--;
hine 25, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 15)--;
line 32, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 17)--;
hine 33, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 18)--;
hine 37, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 19)--; and
line 25, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 19)--; and
```

## IN THE CLAIMS

Please amend the claims as follows:

- 1. (Amended) An isolated substantially homogeneous human mpl ligand polypeptide.
- 2. (Amended) An isolated substantially homogeneous human mpl ligand characterized in that:
  - the ligand stimulates the incorporation of labeled nucleotides (<sup>3</sup>H-thymidine) into the DNA of IL-3 dependent Ba/R3 cells transfected with human mpl P;
  - (2) the ligand is stable to pH 2.5, SDS at 0.1%, and 2M urea;
  - (3) the ligand is a glycoprotein; and
  - (4) the amino-terminal sequence of the polypeptide is [selected from the group

SPAPPACDPRLLNKLLRDDHVLHGR (SEQ ID NO: 6); and

SPAPPACDLRVLS (LRDDHVLHSRL)

SPAPPACDLRVLSKLARDSHVLHSRL (SEQ ID NO: 2).

3. (Amended) An isolated <u>human mpl ligand</u> polypeptide comprising the amino-terminal sequence [SPAPPACDLRVLSKLLRDDHVLHSRL] <u>SRAPPACDLRVLSKLLRDSHVLHSRL</u> (SEQ ID NO: 2).

In claim 6, line 3, delete "(SEQ ID NO: \*)" and insert -- (SEQ ID NO: 4)--.

